	Application No.	Applicant(s)	
	10/072,681	BURTON ET AL.	
Notice of Allowability	Examiner	Art Unit	
	Abdel A. Mohamed	1653	
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI	(OR REMAINS) CLOSED in this app or other appropriate communication IGHTS. This application is subject to	olication. If not included will be mailed in due course. <b>TH</b>	
1. $\boxtimes$ This communication is responsive to <u>response and termina</u>	al disclaimer of10/17/03 and telepho	nic interview of 11/26/03.	
2. The allowed claim(s) is/are <u>1-20</u> .			
3. The drawings filed on <u>08 February 2002</u> are accepted by the			
<ol> <li>Acknowledgment is made of a claim for foreign priority ur</li> <li>a) ☐ All b) ☐ Some* c) ☐ None of the:</li> </ol>	nder 35 U.S.C. § 119(a)-(d) or (f).		
<ol> <li>Certified copies of the priority documents have</li> </ol>	been received.		
<ol><li>Certified copies of the priority documents have</li></ol>	been received in Application No	·	
<ol> <li>Copies of the certified copies of the priority does</li> <li>International Bureau (PCT Rule 17.2(a)).</li> </ol>	cuments have been received in this i	national stage application from th	е
* Certified copies not received:			
<ol> <li>Acknowledgment is made of a claim for domestic priority ur reference was included in the first sentence of the specifica</li> </ol>			
(a) The translation of the foreign language provisional a			
<ol> <li>Acknowledgment is made of a claim for domestic priority up in the first sentence of the specification or in an Application</li> </ol>		nce a specific reference was inclu	nded
Applicant has THREE MONTHS FROM THE "MAILING DATE" of below. Failure to timely comply will result in ABANDONMENT of			
<ol> <li>A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give</li> </ol>			
<ol> <li>CORRECTED DRAWINGS (as "replacement sheets") mus</li> <li>(a) including changes required by the Notice of Draftspers</li> <li>hereto or 2) to Paper No</li> </ol>		948) attached	
(b) $\square$ including changes required by the proposed drawing c	orrection filed, which has be	en approved by the Examiner.	
(c) ☐ including changes required by the attached Examiner's	s Amendment / Comment or in the O	ffice action of Paper No	
Identifying indicia such as the application number (see 37 CFR 1, each sheet. Replacement sheet(s) should be labeled as such in the			
<ol> <li>DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT FOR TO</li> </ol>	sit of BIOLOGICAL MATERIAL n HE DEPOSIT OF BIOLOGICAL MA	nust be submitted. Note the FERIAL.	
Attachment(s)			
1☐ Notice of References Cited (PTO-892)	5☐ Notice of Informal Par	tent Application (PTO-152)	
2 Notice of Draftperson's Patent Drawing Review (PTO-948)	6⊠ Interview Summary (F	PTO-413), Paper No. <u>12</u> .	
3 Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No	), 7⊠ Examiner's Amendme	ent/Comment	
4☐ Examiner's Comment Regarding Requirement for Deposit	_	t of Reasons for Allowance	
of Biological Material		Phin top for VS St.  RISTOPHER S. F. LOW  VISORY PATENT EXAMINER  HNOLOGY CENTER 1800	

Application/Control Number: 10/072,681 Page 2

Art Unit: 1653

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided

by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be

submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview

with James A. Fox on 11/26/03.

In the claims:

Claim 4, line 2, change "Sepharose" to -agarose.--.

Claim 8, line 2, change "SDS-PAGE" to -sodium deodecyl sulphate-

polyacrylamide gel electrophoresis (SDS-PAGE)--.

Claim 11, line 2, change "sepharose" to -agarose--; also in line 2, delete -(SP-

Sepharose HP)--.

Claim 16, line 2, change "NGF" to -nerve growth factor (NGF)--.

Claim 17, line 3, change "NGF, NT-4/5, NT-3, BDNF," to -nerve growth factor

(NGF), neurotrophin-4/5 (NT-4/5), neurotrophin-3 (NT-3), brain-derived neurotrophic

factor (BDNF),--.

CHRISTOPHER S. F. LOW SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1800